NASDAQ NMS - GLOBAL MARKET · ALGS
+3.90% · +$0.2600 · Vol 33.2K
Market closed · last close 4:00 PM ET · price as of 16:00:00 ET
Aligos Therapeutics Inc

Aligos Therapeutics Inc

Biotechnology
$6.93
Card
Relationship Map

Veridion Score

BETALOW CONF · 6/6 factorsMethodology
ALGS
Aligos Therapeutics Inc
Mon Aug 24 · last completed session · Markets closed · resumes Tue 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 6/6 factors with data · Mon Aug 24 · last completed session · Markets closed · resumes Tue 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ALGS moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ALGS catalysts
About Aligos Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2020
Employees
82
Country
US

Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$6.61
Day high
$7.00
Day low
$6.40
Previous close
$6.67
52W high
$13.29
-47.88% from high
52W low
$4.08
31% of range
Market cap
$41.7M
EPS
$-6.9200
Beta
1.26
Shares out
6.2M
Volume
33.2K
0.26× rel vol
Avg volume
127.8K
VWAP
$6.81
Price history computed in-house
1W
+2.51%
1M
+69.85%
3M
+23.75%
1Y
-32.13%
YTD
-25.64%
SMA 50 $5.70 · above
SMA 200 $7.15 · below
52W position 31%

ALGS overview

Veridion Score
59
Registered · 2026-08-24
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ALGS.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ALGS Form 4 filings
Public disclosures

Congress activity in ALGS

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for ALGS in the cached public ledger.

Federal contracts

ALGS contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ALGS in this window.
Lobbying spend

ALGS lobbying filings, year to date.

Registered lobbying filings matched to Aligos Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ALGS in this window.
Loading news for ALGS
Analyst ratings
Sovereign unlock shows live analyst consensus for ALGS.
Options
Sovereign unlock shows live options positioning for ALGS.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.